Alvotech (ICE: ALVO)

Market Cap	513.72B
Revenue (ttm)	15.89B
Net Income (ttm)	-68.65B
Shares Out	301.94M
EPS (ttm)	-294.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1,685.00
Previous Close	1,675.00
Day's Range	1,675.00 - 1,715.00
52-Week Range	1,120.00 - 2,500.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2024

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The company’s platform is designed to enable it to execute the product development and scale-up process in-house: from identifying therapeutic areas and target product candidates with significant unmet patient and market need through R&D, leveraging gold-standard host cell lines, cell-culture processes and Good Manufacturing Practice (GMP) manufacturing, clinical testing, and regulatory approvals. In order to give its products global reach...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 999
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: ALVO

Financial Performance

In 2023, Alvotech's revenue was $93.38 million, an increase of 9.84% compared to the previous year's $85.02 million. Losses were -$551.73 million, 7.43% more than in 2022.

Financial numbers in USD